Background Recently, the Food and Drug Administration issued a recall for the subcutaneous implantable cardioverter-defibrillator (S-ICD) because of the possibility of lead ruptures and accelerated battery depletion. Objective The aim of this study was to evaluate device-related complications over time in a large real-world multicenter S-ICD cohort. Methods Patients implanted with an S-ICD from January 2015 to June 2020 were enrolled from a 19-institution European registry (Experience from the Long-term Italian S-ICD registry [ELISIR]; ClinicalTrials.gov identifier NCT0473876). Device-related complication rates over follow-up were collected. Last follow-up of patients was performed after the Boston Scientific recall issue. Results A total of 1254 patients (median age 52.0 [interquartile range 41.0–62.2] years; 77.6% men; 30.9% ischemic) was enrolled. Over a follow-up of 23.2 (12.8–37.8) months, complications were observed in 117 patients (9.3%) for a total of 127 device-related complications (23.6% managed conservatively and 76.4% required reintervention). Twenty-seven patients (2.2%) had unanticipated generator replacement after 3.6 (3.3–3.9) years, while 4 (0.3%) had lead rupture. Body mass index (hazard ratio [HR] 1.063 [95% confidence interval 1.028–1.100]; P = .000), chronic kidney disease (HR 1.960 [1.191–3.225]; P = .008), and oral anticoagulation (HR 1.437 [1.010–2.045]; P = .043) were associated with an increase in overall complications, whereas older age (HR 0.980 [0.967–0.994]; P = .007) and procedure performed in high-volume centers (HR 0.463 [0.300–0.715]; P = .001) were protective factors. Conclusion The overall complication rate over 23.2 months of follow-up in a multicenter S-ICD cohort was 9.3%. Early unanticipated device battery depletions occurred in 2.2% of patients, while lead fracture was observed in 0.3%, which is in line with the expected rates reported by Boston Scientific.
Long term complications in patients implanted with subcutaneous implantable defibrillators Real-world data from the Extended ELISIR experience / A. Gasperetti, M. Schiavone, M. Ziacchi, J. Vogler, A. Breitenstein, M. Laredo, P. Palmisano, D. Ricciardi, G. Mitacchione, P. Compagnucci, A. Bisignani, A. Angeletti, M. Casella, F. Picarelli, T. Fink, L. Kaiser, S. Hakmi, L. Calò, C. Pignalberi, L. Santini, C. Lavalle, E. Pisanò, I. Olivotto, C. Tondo, A. Curnis, A.D. Russo, N. Badenco, J. Steffel, C.J. Love, R. Tilz, G. Forleo, M. Biffi. - In: HEART RHYTHM. - ISSN 1547-5271. - (2021), pp. 1-9. [Epub ahead of print] [10.1016/j.hrthm.2021.07.008]
Long term complications in patients implanted with subcutaneous implantable defibrillators Real-world data from the Extended ELISIR experience
A. GasperettiPrimo
;M. SchiavoneSecondo
;C. Tondo;
2021
Abstract
Background Recently, the Food and Drug Administration issued a recall for the subcutaneous implantable cardioverter-defibrillator (S-ICD) because of the possibility of lead ruptures and accelerated battery depletion. Objective The aim of this study was to evaluate device-related complications over time in a large real-world multicenter S-ICD cohort. Methods Patients implanted with an S-ICD from January 2015 to June 2020 were enrolled from a 19-institution European registry (Experience from the Long-term Italian S-ICD registry [ELISIR]; ClinicalTrials.gov identifier NCT0473876). Device-related complication rates over follow-up were collected. Last follow-up of patients was performed after the Boston Scientific recall issue. Results A total of 1254 patients (median age 52.0 [interquartile range 41.0–62.2] years; 77.6% men; 30.9% ischemic) was enrolled. Over a follow-up of 23.2 (12.8–37.8) months, complications were observed in 117 patients (9.3%) for a total of 127 device-related complications (23.6% managed conservatively and 76.4% required reintervention). Twenty-seven patients (2.2%) had unanticipated generator replacement after 3.6 (3.3–3.9) years, while 4 (0.3%) had lead rupture. Body mass index (hazard ratio [HR] 1.063 [95% confidence interval 1.028–1.100]; P = .000), chronic kidney disease (HR 1.960 [1.191–3.225]; P = .008), and oral anticoagulation (HR 1.437 [1.010–2.045]; P = .043) were associated with an increase in overall complications, whereas older age (HR 0.980 [0.967–0.994]; P = .007) and procedure performed in high-volume centers (HR 0.463 [0.300–0.715]; P = .001) were protective factors. Conclusion The overall complication rate over 23.2 months of follow-up in a multicenter S-ICD cohort was 9.3%. Early unanticipated device battery depletions occurred in 2.2% of patients, while lead fracture was observed in 0.3%, which is in line with the expected rates reported by Boston Scientific.File | Dimensione | Formato | |
---|---|---|---|
long term.pdf
Open Access dal 15/07/2021
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
8.53 MB
Formato
Adobe PDF
|
8.53 MB | Adobe PDF | Visualizza/Apri |
1-s2.0-S154752712101866X-main.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
1.58 MB
Formato
Adobe PDF
|
1.58 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.